ERAS ERASCA INC

Erasca to Present at Upcoming Investor Conferences

Erasca to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.

Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)

Location: InterContinental Hotel, Boston, MA

Format: Fireside Chat

Date and Time: Tuesday, November 12, 2:00 pm Eastern Time

Jefferies London Healthcare Conference (November 19 – 21, 2024)

Location: The Waldorf Hilton, London, UK

Format: Presentation

Date and Time: Wednesday, November 20, 12:30 pm Greenwich Mean Time

7th Annual Evercore HealthCONx Conference (December 3 – 5, 2024)

Location: Loews Coral Gables Hotel, Coral Gables, FL

Format: Fireside Chat

Date and Time: Wednesday, December 4, 11:15 am Eastern Time

A live audio webcast of the events will be available online at . An archived replay of the events will be available for 90 days following the webcast at .

About Erasca

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:

Joyce Allaire

LifeSci Advisors, LLC

Source: Erasca, Inc.



EN
05/11/2024

Underlying

ERASERASCA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ERASCA INC

 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Me...

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to...

March 25, 2025 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and ...

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precisi...

March 20, 2025 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Confer...

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also part...

January 31, 2025 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also participate in one-on-one ...

January 7, 2025 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Reports Third Quarter 2024 Business Updates and Financial Resul...

Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eras...

November 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch